Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Teppei Yamaguchi

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Cell|October 4, 2011
A DNA repair complex functions as an Oct4/Sox2 coactivator in embryonic stem cellsYick W Fong, Carla Inouye, Teppei Yamaguchi, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysisTeppei Yamaguchi, Junichi Shimizu, Takaaki Hasegawa, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 15, 2016
Short hydration regimen with magnesium supplementation prevents cisplatin-induced nephrotoxicity in lung cancer: a retrospective analysisTeppei Yamaguchi, Sakurako Uozu, Sumito Isogai, et al.
Genes & Development|March 3, 2010
Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progressionTeppei Yamaguchi, Fabien Cubizolles, Yu Zhang, et al.
Thoracic Cancer|January 19, 2022
Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysisTeppei Yamaguchi, Junichi Shimizu, Yuko Oya, et al.
Frontiers in Oncology|June 26, 2024
The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic reviewYutaka Fujiwara, Kazuhiro Shimomura, Teppei Yamaguchi, et al.
Journal of Thoracic Disease|June 17, 2024
Atezolizumab and nintedanib in patients with non-small cell lung cancer and interstitial lung diseaseTeppei Yamaguchi, Junichi Shimizu, Fumie Shigematsu, et al.
BMC Cancer|August 17, 2021
Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysisTeppei Yamaguchi, Junichi Shimizu, Takaaki Hasegawa, et al.
Case Reports in Oncology|October 30, 2024
Long-Term Response of Lorlatinib to Leptomeningeal Metastasis in Patients with Anaplastic Lymphoma Kinase Fusion Positive Non-Small Lung Cancer: A Case ReportYutaka Fujiwara, Katsuhiro Masago, Reiko Matsuzawa, et al.
Scientific Reports|November 26, 2016
Histone deacetylase 1 plays a predominant pro-oncogenic role in Eμ-myc driven B cell lymphomaVincent Pillonel, Nina Reichert, Chun Cao, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Cell|October 4, 2011
A DNA repair complex functions as an Oct4/Sox2 coactivator in embryonic stem cellsYick W Fong, Carla Inouye, Teppei Yamaguchi, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysisTeppei Yamaguchi, Junichi Shimizu, Takaaki Hasegawa, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 15, 2016
Short hydration regimen with magnesium supplementation prevents cisplatin-induced nephrotoxicity in lung cancer: a retrospective analysisTeppei Yamaguchi, Sakurako Uozu, Sumito Isogai, et al.
Genes & Development|March 3, 2010
Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progressionTeppei Yamaguchi, Fabien Cubizolles, Yu Zhang, et al.
Thoracic Cancer|January 19, 2022
Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysisTeppei Yamaguchi, Junichi Shimizu, Yuko Oya, et al.
Frontiers in Oncology|June 26, 2024
The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic reviewYutaka Fujiwara, Kazuhiro Shimomura, Teppei Yamaguchi, et al.
Journal of Thoracic Disease|June 17, 2024
Atezolizumab and nintedanib in patients with non-small cell lung cancer and interstitial lung diseaseTeppei Yamaguchi, Junichi Shimizu, Fumie Shigematsu, et al.
BMC Cancer|August 17, 2021
Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysisTeppei Yamaguchi, Junichi Shimizu, Takaaki Hasegawa, et al.
Case Reports in Oncology|October 30, 2024
Long-Term Response of Lorlatinib to Leptomeningeal Metastasis in Patients with Anaplastic Lymphoma Kinase Fusion Positive Non-Small Lung Cancer: A Case ReportYutaka Fujiwara, Katsuhiro Masago, Reiko Matsuzawa, et al.
Scientific Reports|November 26, 2016
Histone deacetylase 1 plays a predominant pro-oncogenic role in Eμ-myc driven B cell lymphomaVincent Pillonel, Nina Reichert, Chun Cao, et al.
Pageof 6